CRVL
Get informed when a big investor buys or sells
+ FollowOvervalued by 14.9% based on the discounted cash flow analysis.
| Market cap | $2.97 Billion |
|---|---|
| Enterprise Value | $2.75 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.15 |
| Beta | 0.98 |
| Outstanding Shares | 51,150,000 |
| P/E Ratio | 27.22 |
|---|---|
| PEG | 156 |
| Price to Sales | 3.44 |
| Price to Book Ratio | 8.85 |
| Enterprise Value to Revenue | 2.87 |
| Enterprise Value to EBIT | 26.03 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 12,300▲ Infinity% |
Holdings and activity of institutional investors.
| Ownership % | 52.62%▼ 0.03% |
|---|---|
| Total Invested | $1.48B▼ 19.25% |
| Investors Holding | 281▼ 6.00% |
No data
Controls Medicare and Medicaid policy; decisions on whether to expand dental benefits under these programs represent the largest potential volume catalyst for labs.
Regulates the FDA, which provides oversight for dental devices and materials; also influences labor costs and workplace safety in labs.
Focuses on issues affecting seniors, including dental health and the affordability of dentures/prosthetics, often driving legislative interest in Medicare dental coverage.